ZIM
RLAY icon

Zacks Investment Management’s Relay Therapeutics RLAY Stock Holding History

Zacks Investment Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,307
Closed -$53K – 834
2025
Q2 		$53K Buy
+15,307
New +$45.5K ﹤0.01% 680

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Zacks Investment Management's RLAY Position: Q3 2025 in Review

Zacks Investment Management sold out of Relay Therapeutics (RLAY) in Q3 2025, closing a stake of 15,307 shares — an estimated $53K sold.

Zacks Investment Management first reported a position in RLAY in Q2 2025 and held it in 1 quarter. The position peaked at $53K in Q2 2025. 199 funds tracked by Wall St. Rank hold RLAY as of Q3 2025.

  • Zacks Investment Management reported no remaining Relay Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Zacks Investment Management sold 15,307 Relay Therapeutics shares in Q3 2025, an estimated $53K.
  • Zacks Investment Management first reported a position in Relay Therapeutics in Q2 2025 and held it in 1 quarter.
  • Zacks Investment Management's Relay Therapeutics position peaked at $53K in Q2 2025.
  • 199 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2025.

Based on Zacks Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.